We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+2.04%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$23.3B
AUM Growth
-$265M
Cap. Flow
-$917M
Cap. Flow %
-3.93%
Top 10 Hldgs %
47.97%
Holding
197
New
23
Increased
32
Reduced
40
Closed
30

Sector Composition

Rank Sector Weight
1 Healthcare 29.33%
2 Technology 12.47%
3 Financials 9.64%
4 Industrials 5.44%
5 Communication Services 5.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IONS icon
126
Ionis Pharmaceuticals
IONS
$9.4B
$229K ﹤0.01%
4,800
-729,200
-99% -$29.9M
HUM icon
127
Humana
HUM
$46.2B
$224K ﹤0.01%
600
-51,100
-99% -$17.3M
ACLX
128
DELISTED
Arcellx
ACLX
$221K ﹤0.01%
4,000
CHE icon
129
Chemed
CHE
$7.22B
$217K ﹤0.01%
400
SBRA icon
130
Sabra Healthcare REIT
SBRA
$5.37B
$216K ﹤0.01%
14,000
DYN icon
131
Dyne Therapeutics
DYN
$4.9B
$212K ﹤0.01%
+6,000
New +$174K
IOVA icon
132
Iovance Biotherapeutics
IOVA
$2.87B
$209K ﹤0.01%
26,000
SNDX icon
133
Syndax Pharmaceuticals
SNDX
$1.82B
$205K ﹤0.01%
10,000
RNAM
134
DELISTED
Avidity Biosciences
RNAM
$204K ﹤0.01%
5,000
-601,061
-99% -$17.2M
HIMS icon
135
Hims & Hers Health
HIMS
$7.31B
$202K ﹤0.01%
10,000
-1,666,000
-99% -$27.7M
RCM
136
DELISTED
R1 RCM Inc. Common Stock
RCM
$201K ﹤0.01%
16,000
CGC
137
Canopy Growth
CGC
$410M
$194K ﹤0.01%
+30,000
New +$258K
SEDA.WS
138
DELISTED
SDCL EDGE Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A ordinary share at an exercise price of $11.50
SEDA.WS
$191K ﹤0.01%
866,250
PACB icon
139
Pacific Biosciences
PACB
$370M
$185K ﹤0.01%
135,000
-3,637,452
-96% -$7.35M
ALT icon
140
Altimmune
ALT
$599M
$184K ﹤0.01%
27,600
-442,400
-94% -$3.26M
GRFS
141
Grifois
GRFS
$5.4B
$177K ﹤0.01%
28,000
OSCR icon
142
Oscar Health
OSCR
$8.61B
$174K ﹤0.01%
11,000
ARDX icon
143
Ardelyx
ARDX
$997M
$170K ﹤0.01%
23,000
FOLD
144
DELISTED
Amicus Therapeutics
FOLD
$159K ﹤0.01%
16,000
CCCC icon
145
C4 Therapeutics
CCCC
$412M
$129K ﹤0.01%
28,000
BYND icon
146
Beyond Meat
BYND
$277M
$127K ﹤0.01%
19,000
IRWD icon
147
Ironwood Pharmaceuticals
IRWD
$714M
$84.8K ﹤0.01%
13,000
IVCPW
148
DELISTED
Swiftmerge Acquisition Corp. Warrants
IVCPW
$79.2K ﹤0.01%
990,000
CVIIW
149
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
$70K ﹤0.01%
200,000
SLDPW icon
150
Solid Power Inc Warrant
SLDPW
$10.6M
$64.6K ﹤0.01%
405,316

Similar funds

Farallon Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Farallon Capital Management held 197 positions worth $23.3B, down 1.1% from $23.6B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Farallon Capital Management withdrew a net $917M in Q2 2024, closing 30 positions and reducing 40 holdings. Its most notable exit was Pioneer Natural Resource Co., an estimated $924M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 27% a quarter earlier, followed by Technology and Financials.

Against the trend, Farallon Capital Management opened a new position in Walt Disney worth $356M.

  • Farallon Capital Management's largest Q2 2024 buy was Walt Disney: 3,582,168 shares worth $356M.
  • Farallon Capital Management added most to Aon in Q2 2024, an estimated $368M increase.
  • Farallon Capital Management's biggest Q2 2024 reduction was Alphabet (Google) Class C, cutting an estimated $262M.
  • Farallon Capital Management fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $924M.
  • Farallon Capital Management's ten largest holdings make up 48% of its $23.3B portfolio in Q2 2024.
  • Farallon Capital Management opened 23 new positions and closed 30 in Q2 2024.
  • Farallon Capital Management's portfolio value fell 1.1% quarter-over-quarter to $23.3B.

Based on Farallon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.